{
    "nct_id": "NCT03003962",
    "official_title": "A Phase III Randomized, Open-Label, Multi-Center Study of Durvalumab (MEDI4736) Versus Standard of Care (SoC) Platinum-Based Chemotherapy as First Line Treatment in Patients With PD-L1-High Expression Advanced Non Small-Cell Lung Cancer",
    "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "* Prior chemotherapy or any other systemic therapy for advanced NSCLC\n* Prior exposure to immune-mediated therapy, including, but not limited to, other anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), anti-programmed cell death1 (PD-1), anti-programmed cell death ligand 1 (PD-L1), or anti PD-L2 antibodies, excluding therapeutic anticancer vaccines\n* Brain metastases or spinal cord compression unless the patient is stable and off steroids for at least 14 days prior to start of study treatment\n* Mixed small-cell lung cancer and NSCLC histology, sarcomatoid variant\n* Active or prior documented autoimmune or inflammatory disorders (e.g., colitis or Crohn's disease]",
    "miscellaneous_criteria": "Inclusion Criteria\n\n* Aged at least 18 years\n* Documented evidence of Stage IV NSCLC\n* No sensitizing EGFR mutation and ALK rearrangement\n* PD-L1 high expression\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1"
}